Medical OncologyEtoricoxib and Intermittent Androgen Deprivation Therapy in Patients with Biochemical Progression After Radical Prostatectomy
Section snippets
Patients
This was a comparative, prospective, single-center study. Inclusion into this study was based on the following criteria: histologically proven adenocarcinoma of the prostate at surgery, clinically localized prostate cancer, no preoperative hormone therapy, radical prostatectomy at our institution, and biochemical failure after surgery. Between April 2004 and September 2005, a total of 44 patients fulfilled the inclusion criteria and were included in the study. After RRP, serum PSA measurements
Results
A total of 44 patients with PSA progression from an undetectable PSA after RRP were evaluated and randomized in the two groups of treatment. All patients responded to their first 12 weeks of treatment with bicalutamide and serum PSA dropped to a median level of 0.20 ng/mL in group A and 0.15 ng/mL in group B (P = 0.4117). At present, 7 of 44 (15.9%) patients have failed to respond to reinstitution (on-phase) of treatment. All these cases had subsequently been withdrawn from IAD and are
Discussion
To our knowledge, this study represents the first experience in the literature using a COX-2 inhibitor during the off-phases of IAD therapy for prostate adenocarcinoma. Our hypothesis was to use a COX-2 inhibitor to improve the whole response to IAD and, in particular, to prolong the time of the off-phases. The intermittent administration of IAD therapy is not modified and its rationale is respected. Our aims in the administration of the COX-2 inhibitor in association with androgen deprivation
References (21)
- et al.
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model
J Steroid Biochem Mol Biol
(1996) - et al.
Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis
Eur Urol
(2003) - et al.
Cyclooxygenase 1 and 2 isoenzymes
Int J Biochem Cell Biol
(1999) - et al.
Cyclooxygenase 2 and prostate carcinogenesis
Cancer Lett
(2003) - et al.
Expression of cyclooxygenase 1 and 2 in human prostate
Urology
(2000) - et al.
Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase 2
Cell
(1995) - et al.
Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long term experience
Urology
(2005) - et al.
EAU guidelines on prostate cancer
Eur Urol
(2005) - et al.
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report
Urology
(1995) - et al.
Intermittent endocrine therapy for advanced prostate cancer
Cancer
(1986)